advanced Parkinson’s disease Archives

Illustration of a futuristic biotech bear in a forest alongside a princess and armored knight, symbolizing the growing investment opportunity in durable drug-delivery therapies for retinal disease, eosinophilic esophagitis, and Parkinson’s disease.

Biotech’s Durability Trade Is Getting Interesting: Kodiak, Eupraxia and Serina Put the Burden of Treatment in Focus -( $ABBV $EPRX $IBB $KOD $SER $XBI )

by John F. Heerdink, Jr. 3 hours ago 123Views 0Likes

The biotech market has long rewarded breakthrough efficacy. Increasingly, it is also rewarding something patients and physicians understand with unusual clarity: less treatment burden. Fresh clinical updates from Kodiak Sciences Inc. (NASDAQ: KOD), Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX), and Serina Therapeutics Inc. (NYSE…

Illustration of a brain transitioning from a cracked, burdened form to a vibrant neural network, symbolizing advanced Parkinson’s disease treatment innovation, continuous dopamine therapy and improved drug delivery.

Serina Therapeutics Advances SER-252 in Advanced Parkinson’s Disease as Continuous Therapy Market Expands -( $ABBV $SER )

by John F. Heerdink, Jr. 3 days ago 337Views 0Likes

SER-252 enters Cohort 2 with blinded early observations that support the central premise: sustained delivery of a proven Parkinson’s medicine may be far more valuable when it asks less of patients and caregivers. In biotechnology, there are moonshots, and then there are…

Promotional graphic for Tribe Public’s CEO presentation and Q&A webinar, “A New Approach to Advanced Parkinson’s Disease: Exploring SER-252’s Clinical Progress,” featuring Serina Therapeutics CEO Steven Ledger; September 24, 2026, at 8:30 a.m. PT / 11:30 a.m. ET.

Serina Therapeutics Puts Advanced Parkinson’s Disease in the Spotlight – Thursday, September 24

by John F. Heerdink, Jr. 5 days ago 151Views 0Likes

Parkinson’s disease is one of medicine’s most stubborn commercial and scientific frontiers, and Serina Therapeutics, Inc. (NYSE American: SER) is positioning its lead program, SER-252, squarely in the middle of that opportunity. The clinical-stage biotechnology company has opened registration for a Tribe Public CEO…

Comic-book-style Wall Street illustration featuring a charging bull superhero, symbols of insider conviction and high-speed OLED technology, virtual-care clinicians, and a scientist representing Parkinson’s disease research, beneath the headline “Wall Street’s Bullish New Menu.”

Wall Street’s Bullish New Menu: Insider Conviction, OLED Speed, Virtual Care and a Parkinson’s Catalyst -( $AMWL $GME $LPL $PFE $SER $XBI )

by John F. Heerdink, Jr. September 22, 2026 234Views 0Likes

The market’s most compelling bullish narratives rarely arrive wearing the same uniform. This week, they span a CEO buying millions of dollars of his own stock, an OLED display running at a downright impolite 720Hz, a telehealth company pursuing large institutional accounts,…

Tribe Public CEO Presentation and Q&A webinar graphic featuring Serina Therapeutics CEO Steven Ledger, NYSE: SER, promoting “A New Approach to Advanced Parkinson’s Disease: Exploring SER-252’s Clinical Progress,” with a global network map, molecular imagery, and Register Now call to action.

Serina Therapeutics Brings a Fresh Dose of Momentum to Advanced Parkinson’s Care -( $SER $PFE $XBI )

by John F. Heerdink, Jr. September 21, 2026 298Views 0Likes

Serina Therapeutics, Inc. (NYSE American: SER) is approaching a consequential clinical milestone with SER-252, its long-acting POZ-apomorphine candidate for advanced Parkinson’s disease, now advancing into Cohort 2 of a registrational Phase 1b study. For many, the appeal is not simply that Serina is pursuing…

Serina Therapeutics Clears a Key Parkinson’s Hurdle -( $PFE $SER $XBI )

by John F. Heerdink, Jr. September 9, 2026 374Views 0Likes

Serina Therapeutics, Inc. (NYSE American: SER) has moved its lead Parkinson’s disease program from promise on paper to progress in patients. After an independent safety committee completed its blinded review of the first cohort in the Company’s Phase 1b registrational study, Serina received…

Illustration of an older man with Parkinson’s symptoms beside a laboratory researcher holding a syringe, with a large brain diagram showing dopamine pathways, sustained drug release, motor control, and Serina Therapeutics’ Parkinson’s disease drug-delivery innovation.

Serina Therapeutics: A Parkinson’s Story Where Better Drug Delivery Could Become the Main Event -( $PFE $SER $XBI )

by John F. Heerdink, Jr. September 8, 2026 266Views 0Likes

Serina Therapeutics, Inc. (NYSE American: SER) is building a potentially compelling clinical and platform-driven story around a familiar biotech proposition: take a medicine with demonstrated utility, improve the way it behaves in the body, and create a product patients may find meaningfully…

Tag: advanced Parkinson’s disease

Biotech’s Durability Trade Is Getting Interesting: Kodiak, Eupraxia and Serina Put the Burden of Treatment in Focus -( $ABBV $EPRX $IBB $KOD $SER $XBI )

Serina Therapeutics Advances SER-252 in Advanced Parkinson’s Disease as Continuous Therapy Market Expands -( $ABBV $SER )

Serina Therapeutics Puts Advanced Parkinson’s Disease in the Spotlight – Thursday, September 24

Wall Street’s Bullish New Menu: Insider Conviction, OLED Speed, Virtual Care and a Parkinson’s Catalyst -( $AMWL $GME $LPL $PFE $SER $XBI )

Serina Therapeutics Brings a Fresh Dose of Momentum to Advanced Parkinson’s Care -( $SER $PFE $XBI )

Serina Therapeutics Clears a Key Parkinson’s Hurdle -( $PFE $SER $XBI )

Serina Therapeutics: A Parkinson’s Story Where Better Drug Delivery Could Become the Main Event -( $PFE $SER $XBI )

Your Guide To Staying Informed In The Markets